EGFR and non-small cell lung carcinoma: For patients with metastatic NSCLC harboring EGFR mutations, the development of EGFR tyrosine kinase inhibitors (TKIs) is an important improvement in therapeutic care, as shown by the increase in the progression-free survival (PFS) and limitation of toxicities using EGFR-TKIs for patients with EGFR-mutated NSCLC compared to chemotherapy [5], especially with the use of osimertinib versus first-line TKIs (gefitinib and erlotinib) [4,6].